## Unimicron

## 2022 Q4 Financial Review

Feb. 22, 2023

## Disclaimer

> Except for statements in respect of historical matters, the statements in this release are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual performance, financial condition or results of operations of Unimicron to be materially different from what may be implied by such forward-looking statements.
$>$ The financial forecasts and forward-looking statements in this release reflect the current belief of Unimicron as of the date of this release and Unimicron undertakes no obligation to update these forecasts and forward-looking statements for events or circumstances that occur subsequent to such date.
$>$ The statements in respect of historical matters may contain unaudited information, which may have certain deficiency or weakness so as not to fairly present financial condition or the result of operations of Unimicron.

## Consolidated Sales \& Gross Margin Trend



## Consolidated Statements of Comprehensive Income - QoQ

|  | Q4-22 | \% | Q3-22 | \% | NTD:M QoQ \% |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net Sales | 36,690 | 100.0 | 37,454 | 100.0 | (2) |
| Cost of sales | $(23,948)$ | (65.3) | $(23,155)$ | (61.8) | 3 |
| Gross Profit | 12,742 | 34.7 | 14,299 | 38.2 | (11) |
| Operating Expenses | $(3,155)$ | (8.5) | $(3,292)$ | (8.8) | (4) |
| Other Income and Expenses | 12 | 0.0 | 27 | 0.1 | (56) |
| Operating Income | 9,599 | 26.2 | 11,034 | 29.5 | (13) |
| Net Non-operating Income and Expenses | (232) | (0.7) | 875 | 2.3 | (127) |
| Income before tax | 9,367 | 25.5 | 11,909 | 31.8 | (21) |
| Income Tax Expense | $(1,459)$ | (3.9) | $(2,865)$ | (7.7) | (49) |
| Net Income | 7,908 | 21.6 | 9,044 | 24.1 | (13) |
| Other Comprehensive Income and Losses | (150) | (0.5) | (246) | (0.6) | 39 |
| Comprehensive Income | 7,758 | 21.1 | 8,798 | 23.5 | (12) |
| Net Income (Loss) Attributable to: |  |  |  |  |  |
| Shareholders of the Parent | 7,360 | 20.1 | 8,562 | 22.9 |  |
| Non-controlling Interests | 548 | 1.5 | 482 | 1.2 |  |
| Net Income | 7,908 | 21.6 | 9,044 | 24.1 |  |
| EBITDA | 12,788 |  | 14,994 |  |  |
| \%(Sales) | 35\% |  | 40\% |  |  |
| EPS (Basic) | 4.99 |  | 5.80 |  |  |
| (Diluted) | 4.66 |  | 5.63 |  |  |

## 4 <br> CONFIDENIAB

Unimicron

## Consolidated Statements of Comprehensive Income - YoY



## Consolidated Balance Sheets

|  | $\begin{gathered} 2022 \\ \text { DEC. } 31 \\ \hline \end{gathered}$ | \% | $\begin{gathered} 2022 \\ \text { SEP. } 30 \end{gathered}$ | \% | $\begin{gathered} 2022 \\ \text { JUN. } 30 \end{gathered}$ | $\begin{gathered} \text { NTD:M } \\ \% \\ \hline \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cash | 61,459 | 28.1 | 56,340 | 26.9 | 49,626 | 25.2 |
| Accounts Receivable | 28,746 | 13.1 | 29,171 | 13.9 | 28,877 | 14.7 |
| Inventories | 12,835 | 5.9 | 14,244 | 6.8 | 13,394 | 6.8 |
| Other Current Assets | 4,548 | 2.1 | 3,462 | 1.7 | 3,740 | 1.9 |
| Long-term Investments | 8,552 | 3.90 | 8,259 | 3.9 | 8,921 | 4.5 |
| Fixed Assets \& Investment Property | 94,510 | 43.2 | 90,892 | 43.4 | 85,336 | 43.4 |
| Total Assets | 218,663 | 100.0 | 209,312 | 100.0 | 196,830 | 100.0 |
| Short-term Loans | 7,945 | 3.6 | 6,237 | 3.0 | 6,494 | 3.3 |
| Long-term Loans-Current | 2,411 | 1.1 | 3,161 | 1.5 | 2,845 | 1.4 |
| Other Current Liabilities | 44,537 | 20.4 | 44,313 | 21.2 | 46,581 | 23.7 |
| Long-term Loans | 24,563 | 11.2 | 24,740 | 11.8 | 25,657 | 13.0 |
| Other Long-term Liabilities | 46,549 | 21.3 | 45,754 | 21.9 | 40,101 | 20.4 |
| Shareholders' Equity | 92,658 | 42.4 | 85,107 | 40.7 | 75,152 | 38.2 |
| Net Inventory |  |  |  |  |  |  |
| Turnover Days | 51 |  | 55 |  | 54 |  |
| Net Accounts Receivable |  |  |  |  |  |  |
| Turnover Days | 68 |  | 70 |  | 72 |  |

## Consolidated Statements Of Cash Flows - QoQ

|  | Q4-22 | $\begin{aligned} & \text { NTD:M } \\ & \text { Q3-22 } \end{aligned}$ |
| :---: | :---: | :---: |
| Income before tax | 9,367 | 11,909 |
| Depreciation and Amortization | 3,272 | 2,973 |
| Others | 1,785 | 4,321 |
| Net Cash Provided by Operating Activities | 14,424 | 19,203 |
| Acquisition of Fix Assets \& Investment Property | $(8,008)$ | $(7,116)$ |
| Increase in Investments | (198) | (14) |
| Others | $(1,383)$ | (64) |
| Net Cash Used by Investing Activities | $(9,589)$ | $(7,194)$ |
| Cash Dividends | 0 | $(5,016)$ |
| Increase (Decrease) in Loans | 950 | $(1,183)$ |
| Others | (330) | 1,012 |
| Net Cash Provided (Used) by Financing Activities | 620 | $(5,187)$ |
| Effect of Exchange Rates Changes | (336) | (108) |
| Increase in Cash | 5,119 | 6,714 |
| Cash at End of Period | 61,459 | 56,340 |

Unimicron

## Consolidated Statements Of Cash Flows - YoY

|  | Q1~Q4-22 | $\begin{aligned} & \text { NTD:M } \\ & \text { Q1~Q4-21 } \end{aligned}$ |
| :---: | :---: | :---: |
| Income before tax | 39,875 | 16,629 |
| Depreciation and Amortization | 11,727 | 9,757 |
| Others | 9,480 | 16,554 |
| Net Cash Provided by Operating Activities | 61,082 | 42,940 |
| Acquisition of Fix Assets \& Investment Property | $(32,073)$ | $(23,167)$ |
| Decrease (Increase) in Investments | (414) | 132 |
| Others | (909) | $(1,404)$ |
| Net Cash Used by Investing Activities | $(33,396)$ | $(24,439)$ |
| Cash Dividends | $(5,016)$ | $(2,055)$ |
| Decrease in Loans | $(3,914)$ | $(9,203)$ |
| Increase in Corporate Bond | 2,996 | 7,990 |
| Others | 1,103 | (716) |
| Net Cash Used by Financing Activities | $(4,831)$ | $(3,984)$ |
| Effect of Exchange Rates Changes | (798) | 691 |
| Increase in Cash | 22,057 | 15,208 |
| Cash at End of Period | 61,459 | 39,402 |

## CONFIDENIIAB

## Sales Breakdown by Technology - QoQ

Sales (NT\$ millions) $\quad-764 \mathrm{M}(-2.0 \%) \downarrow$


## Sales Breakdown by Application - QoQ



Unimicron

## Sales Breakdown by Technology - YoY

Sales (NT\$ millions)
+35,926M (+34.4\%) 个


## Sales Breakdown by Application - YoY

Sales (NT\$ millions)
+35,926M (+34.4\%) 个


## Unimicron

## 謝謝您的聆聽

Thank you

